Is ATEC or CARL more profitable?

Alphatec has a net margin of -13.49% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% Carlsmed -57.42% -38.06% -28.96%

Does the media favor ATEC or CARL?

In the previous week, Carlsmed had 1 more articles in the media than Alphatec. MarketBeat recorded 5 mentions for Carlsmed and 4 mentions for Alphatec. Alphatec's average media sentiment score of 1.57 beat Carlsmed's score of 0.93 indicating that Alphatec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphatec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Carlsmed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, CARL or CNMD?

CONMED has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 8.75 -$29.63M -$1.43 N/A CONMED $1.37B 1.10 $47.06M $1.85 27.33

Is CARL or CNMD more profitable?

CONMED has a net margin of 4.12% compared to Carlsmed's net margin of -57.42%. CONMED's return on equity of 14.31% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.42% -38.06% -28.96% CONMED 4.12% 14.31% 6.33%

Does the media favor CARL or CNMD?

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Carlsmed's average media sentiment score of 0.93 beat CONMED's score of 0.64 indicating that Carlsmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENOV or CARL more profitable?

Enovis has a net margin of -47.96% compared to Carlsmed's net margin of -57.42%. Enovis' return on equity of 12.03% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% Carlsmed -57.42% -38.06% -28.96%

Does the media prefer ENOV or CARL?

In the previous week, Enovis had 4 more articles in the media than Carlsmed. MarketBeat recorded 9 mentions for Enovis and 5 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.93 beat Enovis' score of 0.88 indicating that Carlsmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carlsmed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CARL or IART?

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Integra LifeSciences' average media sentiment score of 1.35 beat Carlsmed's score of 0.93 indicating that Integra LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integra LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CARL or AORT?

Artivion has higher revenue and earnings than Carlsmed. Artivion is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 8.75 -$29.63M -$1.43 N/A Artivion $441.33M 3.01 $9.77M -$0.07 N/A

Is CARL or AORT more profitable?

Artivion has a net margin of -0.67% compared to Carlsmed's net margin of -57.42%. Artivion's return on equity of 6.07% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.42% -38.06% -28.96% Artivion -0.67% 6.07% 2.93%

Does the media prefer CARL or AORT?

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Artivion's average media sentiment score of 1.08 beat Carlsmed's score of 0.93 indicating that Artivion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Carlsmed (CARL) Competitors

$16.18 +0.11 (+0.68%)

As of 04:00 PM Eastern

Compare

CARL vs. ATEC, CNMD, ENOV, IART, and AORT

Should you buy Carlsmed stock or one of its competitors? Carlsmed's main competitors and comparable companies include Alphatec (ATEC), CONMED (CNMD), Enovis (ENOV), Integra LifeSciences (IART), and Artivion (AORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Carlsmed compare to Alphatec?

Alphatec (NASDAQ:ATEC) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Alphatec currently has a consensus price target of $17.40, indicating a potential upside of 84.71%. Carlsmed has a consensus price target of $19.25, indicating a potential upside of 18.97%. Given Alphatec's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alphatec is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.4% of Alphatec shares are owned by institutional investors. 13.5% of Alphatec shares are owned by company insiders. Comparatively, 12.9% of Carlsmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alphatec has a net margin of -13.49% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
Carlsmed	-57.42%	-38.06%	-28.96%

Carlsmed has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	1.90	-$143.36M	-$0.71	N/A
Carlsmed	$50.51M	8.75	-$29.63M	-$1.43	N/A

In the previous week, Carlsmed had 1 more articles in the media than Alphatec. MarketBeat recorded 5 mentions for Carlsmed and 4 mentions for Alphatec. Alphatec's average media sentiment score of 1.57 beat Carlsmed's score of 0.93 indicating that Alphatec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Carlsmed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alphatec beats Carlsmed on 10 of the 15 factors compared between the two stocks.

How does Carlsmed compare to CONMED?

Carlsmed (NASDAQ:CARL) and CONMED (NYSE:CNMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Carlsmed's average media sentiment score of 0.93 beat CONMED's score of 0.64 indicating that Carlsmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Carlsmed currently has a consensus target price of $19.25, indicating a potential upside of 18.97%. CONMED has a consensus target price of $41.40, indicating a potential downside of 18.12%. Given Carlsmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Carlsmed is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

CONMED has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	8.75	-$29.63M	-$1.43	N/A
CONMED	$1.37B	1.10	$47.06M	$1.85	27.33

CONMED has a net margin of 4.12% compared to Carlsmed's net margin of -57.42%. CONMED's return on equity of 14.31% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
CONMED	4.12%	14.31%	6.33%

Summary

CONMED beats Carlsmed on 7 of the 12 factors compared between the two stocks.

How does Carlsmed compare to Enovis?

Enovis (NYSE:ENOV) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Enovis has a net margin of -47.96% compared to Carlsmed's net margin of -57.42%. Enovis' return on equity of 12.03% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Carlsmed	-57.42%	-38.06%	-28.96%

Enovis currently has a consensus price target of $41.29, suggesting a potential upside of 63.77%. Carlsmed has a consensus price target of $19.25, suggesting a potential upside of 18.97%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Enovis had 4 more articles in the media than Carlsmed. MarketBeat recorded 9 mentions for Enovis and 5 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.93 beat Enovis' score of 0.88 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Carlsmed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Carlsmed has lower revenue, but higher earnings than Enovis. Carlsmed is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.65	-$1.18B	-$19.26	N/A
Carlsmed	$50.51M	8.75	-$29.63M	-$1.43	N/A

98.5% of Enovis shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Enovis beats Carlsmed on 10 of the 15 factors compared between the two stocks.

How does Carlsmed compare to Integra LifeSciences?

Carlsmed (NASDAQ:CARL) and Integra LifeSciences (NASDAQ:IART) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Carlsmed has higher earnings, but lower revenue than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	8.75	-$29.63M	-$1.43	N/A
Integra LifeSciences	$1.64B	0.80	-$516.47M	-$0.09	N/A

Carlsmed presently has a consensus price target of $19.25, suggesting a potential upside of 18.97%. Integra LifeSciences has a consensus price target of $18.86, suggesting a potential upside of 11.71%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88

84.8% of Integra LifeSciences shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Integra LifeSciences has a net margin of -0.44% compared to Carlsmed's net margin of -57.42%. Integra LifeSciences' return on equity of 18.30% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
Integra LifeSciences	-0.44%	18.30%	5.30%

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Integra LifeSciences' average media sentiment score of 1.35 beat Carlsmed's score of 0.93 indicating that Integra LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integra LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Carlsmed and Integra LifeSciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Carlsmed compare to Artivion?

Carlsmed (NASDAQ:CARL) and Artivion (NYSE:AORT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Carlsmed currently has a consensus target price of $19.25, suggesting a potential upside of 18.97%. Artivion has a consensus target price of $44.83, suggesting a potential upside of 64.77%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.4% of Artivion shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Artivion has higher revenue and earnings than Carlsmed. Artivion is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	8.75	-$29.63M	-$1.43	N/A
Artivion	$441.33M	3.01	$9.77M	-$0.07	N/A

Artivion has a net margin of -0.67% compared to Carlsmed's net margin of -57.42%. Artivion's return on equity of 6.07% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
Artivion	-0.67%	6.07%	2.93%

In the previous week, Carlsmed and Carlsmed both had 5 articles in the media. Artivion's average media sentiment score of 1.08 beat Carlsmed's score of 0.93 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artivion beats Carlsmed on 11 of the 14 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARL vs. The Competition

Export

Metric	Carlsmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$438.76M	$5.94B	$7.40B	$12.81B
Dividend Yield	N/A	1.75%	2.53%	11.02%
P/E Ratio	-11.31	25.89	272.19	24.12
Price / Sales	8.75	69.39	631.92	95.39
Price / Cash	N/A	33.21	79.89	53.65
Price / Book	5.24	6.24	13.14	6.20
Net Income	-$29.63M	$149.10M	$3.47B	$348.07M
7 Day Performance	4.25%	0.53%	1.38%	0.67%
1 Month Performance	49.81%	9.26%	8.62%	4.84%
1 Year Performance	N/A	6.82%	25.90%	16.83%

Carlsmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARL Carlsmed	1.7644 of 5 stars	$16.18 +0.7%	$19.25 +19.0%	N/A	$438.76M	$50.51M	N/A	100
ATEC Alphatec	3.8162 of 5 stars	$9.79 +0.4%	$17.40 +77.7%	-41.1%	$1.51B	$764.16M	N/A	700	Positive News
CNMD CONMED	1.5566 of 5 stars	$50.42 +1.2%	$41.40 -17.9%	-6.0%	$1.51B	$1.37B	27.25	3,900	Positive News
ENOV Enovis	4.1175 of 5 stars	$26.08 +1.6%	$42.00 +61.0%	-17.3%	$1.50B	$2.25B	N/A	7,802
IART Integra LifeSciences	1.9156 of 5 stars	$18.34 +0.5%	$18.86 +2.8%	+17.7%	$1.43B	$1.64B	N/A	4,427	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARL) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carlsmed (CARL) Competitors